15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $359700 | -$14M | 93.4% | -4350.1% | -3992.2% | -349.1% | -$11M | — | $2M |
| 2024 | $401000 | -$9M | 93.0% | -2881.6% | -105.3% | -73.1% | -$8M | — | $547890 |
| 2023 | $145800 | -$10M | 100.0% | -10439.5% | -104.1% | -82.6% | -$7M | — | $884377 |
| 2022 | $119800 | -$13M | 0.0% | -15838.1% | -128.5% | -80.5% | -$6M | — | $2M |
| 2021 | $46000 | -$44M | 0.0% | -57191.0% | -410.9% | -197.3% | -$3M | $250000 | $21M |
| 2020 | $77000 | -$11M | 0.0% | -3574.1% | 846.6% | -259.3% | — | — | — |
| 2019 | $130000 | -$15M | 0.0% | -6486.2% | 114.7% | -999.0% | -$7M | — | — |
| 2018 | $111000 | -$13M | 0.0% | -6889.8% | 144.9% | -1049.8% | -$5M | — | — |
| 2017 | $81000 | -$9M | 100.0% | -10338.6% | 138.1% | -537.1% | -$4M | — | — |
| 2016 | — | -$9M | — | — | 172.7% | -546.6% | — | — | — |
| 2015 | — | -$8M | — | — | 202.7% | -392.8% | — | — | — |
| 2014 | — | -$6M | — | — | 81.1% | -330.3% | — | — | — |
| 2014 | — | -$21M | — | — | 307.8% | -1715.4% | -$11M | — | — |
| 2013 | — | -$6M | — | — | 86.0% | -415.9% | -$3M | — | — |
| 2013 | — | -$18M | — | — | 274.2% | -1486.2% | -$9M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Mar '26 | $23170 | -$2M | 68.1% | -14612.6% | -71.2% | -46.4% | — | — | $3M |
| Dec '25 | $19600 | -$3M | 91.7% | -19516.8% | -899.1% | -78.6% | -$2M | — | $2M |
| Sep '25 | $11800 | -$3M | 10.4% | -31432.3% | -137.7% | -53.8% | -$3M | — | $602444 |
| Jun '25 | $303300 | -$3M | 97.1% | -1089.8% | -54.8% | -31.2% | -$3M | — | $2M |
| Mar '25 | $25000 | -$5M | 88.4% | -19230.1% | -86.9% | -51.7% | -$3M | — | $1M |
| Dec '24 | $43300 | -$2M | 92.3% | -6212.8% | -19.2% | -13.3% | -$2M | — | $547890 |
| Sep '24 | $233600 | -$1M | 92.2% | -979.0% | -10.9% | -7.5% | -$2M | — | $1M |
| Jun '24 | $89100 | -$4M | 92.7% | -2770.8% | -37.3% | -25.0% | — | — | $2M |
| Mar '24 | $35000 | -$2M | 100.0% | -11740.7% | -15.3% | -12.4% | — | — | $1M |
| Dec '23 | $19300 | -$2M | 100.0% | -16687.5% | -23.0% | -18.3% | -$2M | — | $884377 |
| Sep '23 | $30700 | $5M | 100.0% | -10112.2% | 44.3% | 34.5% | -$1M | — | $2M |
| Jun '23 | $64500 | -$6M | 100.0% | -4831.9% | -215.9% | -42.9% | -$1M | — | $2M |
| Mar '23 | $31300 | -$7M | 0.0% | -18463.6% | -111.1% | -50.9% | -$2M | — | $2M |
| Dec '22 | $3700 | -$4M | 0.0% | -126537.9% | -42.2% | -26.5% | -$2M | — | $2M |
| Sep '22 | $29000 | -$5M | 0.0% | -15895.5% | -55.7% | -30.4% | -$1M | — | $7M |
| Jun '22 | $71100 | $3M | 0.0% | -6510.0% | 25.5% | 15.9% | -$1M | — | — |
| Mar '22 | $16000 | -$5M | 0.0% | -31586.2% | -80.9% | -23.0% | -$2M | — | — |
| Dec '21 | $5000 | -$20M | 0.0% | -80185.3% | -189.2% | -90.9% | — | $250000 | $21M |
| Sep '21 | $8000 | -$4M | 0.0% | -46108.6% | 85.8% | -192.4% | — | $10M | — |
| Jun '21 | $15000 | -$4M | 0.0% | -23701.8% | 106.7% | -140.8% | — | $10M | — |
How the market has priced BRTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, BioRestorative Therapies, Inc.'s revenue has grown 36.1% per year. These are computed facts, not advice.
As of FY2025, BioRestorative Therapies, Inc. reported — of total debt against $2M of cash.
In FY2025, gross margin was 93.4%, operating margin -4350.1%, and net margin -3959.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.